Caeregen Therapeutics Receives $1.4 Million Phase 2 SBIR Grant from NIH/NEI to Advance Development of Regenerative Medicine Clinical Candidate CTR-107 (Noregen™) for Retinal Diseases

ROCHESTER, Mich.--(BUSINESS WIRE)--Caeregen Therapeutics Receives $1.4 M Phase 2 SBIR Grant to Advance Development of Regenerative Medicine Clinical Candidate for Retinal Diseases